Peptide PCT and Breaks — Off-Cycle Protocol Reference
GHSR downregulation follows GH secretagogue use: standard protocol is 4–8 week break after 8–12 week cycle to restore pituitary axis sensitivity. No human study defines optimal break duration.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| GH Peptide Minimum Break | 4 | weeks minimum | Standard minimum break duration after GH secretagogue cycle; 6–8 weeks preferred; no human study defines exact optimal duration |
| Semaglutide — Weight Regain After Stopping | ~66 | % of lost weight regained | PMID 35441470: STEP 1 extension — 1 year after stopping semaglutide, participants regained ~66% of weight lost; supports chronic use without breaks |
| GH Axis Recovery Time | 4–8 | weeks | Estimated GHSR resensitization period after GH secretagogue discontinuation; no formal human study; community convention based on receptor biology |
| BPC-157 Break Duration | 4–6 | weeks | Matched to cycle duration (4–6 on / 4–6 off); precautionary; no proven receptor desensitization mechanism for BPC-157 |
| IGF-1 Normalization | 2–4 | weeks after stopping GH peptides | Estimated time for GH-driven IGF-1 elevation to return to baseline after cycle end; supports 4-week minimum break |
| PCT Requirement vs Anabolic Steroids | Not required | distinction | Unlike anabolic steroids, GH peptides do not suppress HPT (testosterone) axis; no SERM or hormone therapy needed post-cycle; GH axis break only |
PCT and Breaks — Conceptual Framework
The term “PCT” (post-cycle therapy) originated in anabolic steroid use culture to describe the pharmacological intervention (usually SERMs) needed after steroid cycles to restore suppressed testosterone production. For peptides, the term has been loosely adopted to mean “off-cycle break period” — but the underlying biology is completely different and does not require pharmaceutical hormone therapy.
Understanding which peptides require breaks, why, and for how long is essential for rational protocol design.
Why Breaks Are Required — Mechanism Table
| Mechanism | Peptide Class | Evidence Level | Effect of No Break |
|---|---|---|---|
| GHSR agonist-induced receptor desensitization | GH secretagogues (ipamorelin, GHRP-2, GHRP-6) | C — mechanistically sound; duration evidence is D | Progressive GH pulse attenuation; diminishing returns |
| GHRH receptor desensitization | CJC-1295 | C | Reduced GHRH responsiveness; less pulse amplification |
| Unknown (precautionary) | BPC-157, TB-500 | D | Unknown; no proven desensitization mechanism |
| None — no break required | GLP-1/GIP agonists (semaglutide, tirzepatide) | A | Weight regain (pharmacological effect ceases, not receptor damage) |
| None — no break required | Topical GHK-Cu | B (topical) | No desensitization mechanism identified |
| Short course by design | Semax, Selank | B (Russian practice) | Possible tachyphylaxis at longer use; Russian protocol uses short courses |
GH Peptide Break Reference Table
| Peptide | Typical Cycle | Minimum Break | Preferred Break | Notes |
|---|---|---|---|---|
| Ipamorelin | 8–12 weeks | 4 weeks | 6–8 weeks | Primary cycling peptide; GHSR resensitization |
| CJC-1295 (no DAC) | 8–12 weeks | 4 weeks | 6–8 weeks | Always cycle with GHSR agonist |
| CJC-1295 (DAC) | 8–12 weeks | 6 weeks | 8 weeks | Longer half-life → longer effective tail → longer break |
| GHRP-2 | 8–12 weeks | 4 weeks | 6 weeks | Cortisol co-release during cycle; break recommended |
| GHRP-6 | 8–12 weeks | 4 weeks | 6 weeks | Strong appetite effects during cycle; break welcome |
| MK-677 | 12–16 weeks | 4–6 weeks | 6–8 weeks | Oral; long half-life; desensitization less acute but still applies |
| Ipamorelin + CJC-1295 stack | 8–12 weeks | 4 weeks | 6–8 weeks | Stack pauses together; same break |
Non-GH Peptide Break Reference Table
| Peptide | Break Required? | Recommended Protocol | Rationale |
|---|---|---|---|
| BPC-157 (injury) | Precautionary | 4–6 weeks on / 4–6 weeks off | No mechanism; unknown long-term effects; precautionary |
| TB-500 | Precautionary | 4–6 weeks on / 4–6 weeks off | Same as BPC-157 |
| BPC-157 + TB-500 | Precautionary | 4–6 weeks on / 4–6 weeks off | Synchronized break |
| Semaglutide | No | Chronic continuous dosing | Weight regain upon stopping; receptor intact |
| Tirzepatide | No | Chronic continuous dosing | Same as semaglutide |
| Semax | Yes (short courses) | 10–14 days on / 2–4 weeks off | Russian clinical standard; possible tachyphylaxis |
| Selank | Yes (short courses) | 10–14 days on / 2–4 weeks off | Russian clinical standard |
| Epitalon | Yes (long breaks) | 10–20 days on / 4–6 months off | Khavinson protocol; ~2× per year |
| GHK-Cu (topical) | No strong rationale | Daily topical; no break required | Substrate-driven; no receptor desensitization evidence |
| Collagen peptides | No | Daily; ongoing use acceptable | No pharmacological receptor mechanism |
What to Monitor During a Break
| Biomarker | Relevance | When to Check | Target During Break |
|---|---|---|---|
| IGF-1 | GH axis activity; declines during break | 2–4 weeks post-cycle | Return to pre-cycle baseline |
| Fasting glucose | GH can elevate glucose; should normalize | 2 weeks post-cycle | Normal fasting range |
| Subjective recovery | Sleep quality, energy, body composition | Ongoing | Gradual normalization expected |
| Cortisol (if using GHRP-2) | GHRP-2 co-stimulates cortisol release | 2 weeks post-cycle | Return to baseline |
PCT Distinctions vs Steroids
| Parameter | Anabolic Steroids | GH Peptides | GLP-1/GIP Agonists |
|---|---|---|---|
| Axis suppressed | HPT (testosterone) | GH axis (GHSR) | None |
| PCT drug required? | Yes (SERMs) | No | No |
| Break required? | Yes + PCT | Yes (receptor resensitization) | No |
| Consequence of no break | Hypogonadism | Diminishing GH response | No receptor consequence |
| Consequence of stopping | Hormone crash without PCT | Gradual GH normalization | Condition return (weight regain, etc.) |
Evidence Grade Callout
Grade A: Semaglutide weight regain after stopping (PMID 35441470) — no break protocol required; chronic use is FDA-standard-of-care. Grade C: GH peptide cycling rationale — GHSR desensitization is mechanistically sound but optimal break duration is community convention with no formal human trial data. Grade D: BPC-157/TB-500 break rationale — no proven desensitization mechanism; precautionary convention only.
Legal Disclaimer
Research peptide break protocols are community conventions without clinical validation. FDA-approved peptide pharmaceuticals (semaglutide, tirzepatide) should follow prescribing information, which does not include cycling. Research peptides have no approved protocols. This page is for educational reference and does not constitute medical advice.
Related Pages
Sources
- Bowers CY et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822
- Nass R et al. Evidence for acyl-ghrelin modulation of growth hormone release in the fed and fasted states. J Clin Endocrinol Metab. 2008;93(5):1988-94. PMID 18319316
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-64. PMID 35441470
Frequently Asked Questions
Do peptides require PCT (post-cycle therapy) like anabolic steroids?
No — not in the same sense. Anabolic androgenic steroids suppress the hypothalamic-pituitary-testicular (HPT) axis, which requires post-cycle therapy (SERMs like tamoxifen/clomiphene) to restore endogenous testosterone production. Research peptides, including GH secretagogues, do not suppress testosterone production. The 'break' required after GH peptides is for GHSR receptor resensitization — allowing the pituitary to restore normal GH pulse amplitude — not hormonal axis recovery. The term 'PCT' in the peptide context refers colloquially to the off-cycle break, not pharmaceutical hormone therapy.
What happens if you don't take a break from GH peptides?
Continuous GH secretagogue use without cycling is thought to produce receptor desensitization — progressive reduction in GH pulse amplitude as GHSR downregulates and somatostatin tone increases. Practically, this means diminishing returns: peptides that initially produced noticeable GH effects (improved recovery, body composition changes) become progressively less effective. Additionally, chronically elevated IGF-1 — a downstream effect of sustained GH elevation — is associated with theoretical but uncertain long-term risks. The formal data on continuous-use consequences in humans is limited; the cycling recommendation is precautionary.
Does stopping semaglutide or tirzepatide require a break protocol?
Stopping GLP-1 or GLP-1/GIP agonists has a predictable consequence: weight regain. Wilding et al. (PMID 35441470) showed that 1 year after stopping semaglutide, participants regained approximately 66% of the weight lost during the trial. This is not receptor desensitization — it is the natural consequence of removing a pharmacological appetite suppressant. There is no 'break protocol' that mitigates this; the current evidence-based approach is indefinite chronic use if the treatment is effective, not cycling. GLP-1/GIP agonists are metabolic disease drugs, not performance compounds — the cycling model doesn't apply.